The United States (US) Food and Drug Administration (FDA) has made available an International Council for Harmonisation (ICH) draft guidance on technical and regulatory considerations for pharmaceutical product lifecycle management. Read more “FDA adopts draft ICH guidance for managing post-approval CMC changes”
The United States (US) Food and Drug Administration (FDA) have revised draft guidance on the development and manufacture of inhalation aerosols (also known as metered dose inhalers (MDIs)) and inhalation powders (also known as dry powder inhalers (DPIs)). The guidance describes points to consider in order to ensure product quality and performance for MDIs and DPIs. It states chemistry, manufacturing, and controls (CMC) information recommended for inclusion in new drug applications (NDAs) and abbreviated new drug applications (ANDAs). Read more “FDA revises draft guidance on metered dose and dry powder inhalers”
The US Food and Drug Administration (FDA) has published draft guidance intended to assist applicants and manufacturers of certain licensed biological products in determining which reporting category is appropriate for a change in chemistry, manufacturing, and controls (CMC) information to an approved biologics license application (BLA). Read more “FDA publishes draft guidance on CMC changes to a biologics license application”
The International Council for Harmonisation (ICH) has released a Question & Answers document on its ICH Q11 guideline, Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities).
In 2016, the European Medicines Agency (EMA) announced the publication of a draft guidance on the dissolution requirements for orally administered generics with immediate release characteristics. Read more “EMA publishes reflection paper for generic oral immediate release products”
The Committee for Human Medicinal Product (CHMP) recently adopted an updated guideline on manufacture of the finished dosage form.